FDA clears VVT Medical varicose veins treatment device

The ScleroSafe system [Image courtesy of VVT Medical]VVT Medical announced in recent months that FDA has cleared its ScleroSafe platform, which delivers endovenous chemical ablation to treat superficial varicose veins.

Kfar Saba, Israel–based VVT Medical says it specifically created ScleroSafe to provide efficient, non-thermal, non-tumescent treatment and management of varicosities in superficial veins. Its inverse-action dual syringe injects the ECA substance into the vein through one syringe while simultaneously aspirating blood and substance residuals through the second syringe. ScleroSafe accomplishes all of these actions within a single motion and with single-hand operation.

The company has already received approval for ScleroSafe in multiple regions, including Europe, Australia, Southeast Asia, and South America.

As many as 40 million people in the United States suffer from varicose veins, according to Beth Israel Deaconess Medical Center in Boston. E…

Read more
  • 0